Dimensional Fund Advisors LP Has $104.28 Million Holdings in DexCom, Inc. (NASDAQ:DXCM)

Dimensional Fund Advisors LP raised its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 41.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 919,650 shares of the medical device company’s stock after buying an additional 268,802 shares during the period. Dimensional Fund Advisors LP owned 0.23% of DexCom worth $104,282,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Massachusetts Financial Services Co. MA raised its stake in shares of DexCom by 16.9% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company’s stock valued at $276,538,000 after acquiring an additional 353,019 shares in the last quarter. Rathbones Group PLC raised its position in shares of DexCom by 5.8% in the second quarter. Rathbones Group PLC now owns 1,401,802 shares of the medical device company’s stock valued at $158,936,000 after purchasing an additional 76,727 shares during the period. Nia Impact Advisors LLC lifted its stake in shares of DexCom by 4.5% in the second quarter. Nia Impact Advisors LLC now owns 11,630 shares of the medical device company’s stock worth $1,319,000 after buying an additional 500 shares during the last quarter. MayTech Global Investments LLC boosted its holdings in shares of DexCom by 2.1% during the 2nd quarter. MayTech Global Investments LLC now owns 168,759 shares of the medical device company’s stock worth $19,134,000 after buying an additional 3,511 shares during the period. Finally, Prosperity Consulting Group LLC grew its stake in DexCom by 38.2% in the 2nd quarter. Prosperity Consulting Group LLC now owns 4,857 shares of the medical device company’s stock valued at $551,000 after buying an additional 1,342 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Activity at DexCom

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Michael Jon Brown sold 659 shares of the firm’s stock in a transaction dated Friday, June 28th. The shares were sold at an average price of $114.29, for a total value of $75,317.11. Following the completion of the transaction, the executive vice president now owns 66,901 shares in the company, valued at approximately $7,646,115.29. The disclosure for this sale can be found here. Insiders sold a total of 2,483 shares of company stock valued at $201,708 over the last quarter. Corporate insiders own 0.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on DXCM shares. Piper Sandler reissued an “overweight” rating and set a $90.00 target price on shares of DexCom in a research report on Monday, August 26th. JPMorgan Chase & Co. lowered DexCom from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $145.00 to $75.00 in a report on Friday, July 26th. Canaccord Genuity Group reiterated a “buy” rating and set a $145.00 price target on shares of DexCom in a report on Tuesday, July 23rd. UBS Group lowered their price objective on shares of DexCom from $163.00 to $95.00 and set a “buy” rating on the stock in a research note on Friday, July 26th. Finally, Stifel Nicolaus increased their price target on shares of DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a report on Friday, August 23rd. Six research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $112.25.

DexCom Trading Down 1.5 %

Shares of DXCM opened at $68.66 on Wednesday. The stock has a fifty day moving average price of $76.37 and a two-hundred day moving average price of $108.46. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.48 and a current ratio of 2.82. The company has a market cap of $27.30 billion, a price-to-earnings ratio of 44.30, a PEG ratio of 2.12 and a beta of 1.18. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.04. The business had revenue of $1 billion for the quarter, compared to the consensus estimate of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The firm’s quarterly revenue was up 15.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.34 EPS. Analysts predict that DexCom, Inc. will post 1.69 EPS for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.